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adding clopidogrel had significant net clinical benefit,
with prevention of 0.57-0.67 ischemic stroke equivalents/
100 patient-years. 
Conclusions: There is modest net clinical benefit of adding
clopidogrel to aspirin in patients with AF in whom a VKA
is not suitable. 
Perspective: In the ACTIVE A trial, adding clopidogrel to
aspirin reduced the risk of stroke, but increased the risk for
bleeding compared to aspirin alone. The weighted analysis
used in this study accounts for the variable clinical impor-
tance of events that occur during follow-up, and indicates
that there is net clinical benefit of the clopidogrel-aspirin
combination compared to aspirin alone.
Summary written by: Fred Morady, MD
Atrial Fibrillation Catheter Ablation Versus Surgical
Ablation Treatment (FAST): A 2-Center Randomized
Clinical Trial
Boersma LV, Castella M, van Boven WJ, et al.
Circulation 2011;Nov 14:[Epub ahead of print].
Study Question: Is minimally-invasive surgical ablation (SA)
more effective than radiofrequency catheter ablation
(RFCA) for eliminating atrial fibrillation (AF)? 
Methods: The subjects of the FAST study were 124 patients
(mean age 56 years) with drug-refractory AF (persistent in
33%) and left atrial diameter >40 mm or a prior failed abla-
tion procedure. The patients were randomly assigned to
RFCA (n = 63) or SA (n = 61). RFCA consisted of wide-
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Net Clinical Benefit of Adding Clopidogrel to
Aspirin Therapy in Patients With Atrial Fibrillation
for Whom Vitamin K Antagonists Are Unsuitable
Connolly SJ, Eikelboom JW, Ng J, et al., on behalf of the
ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for
Prevention of Vascular Events) Steering Committee and
Investigators.
Ann Intern Med 2011;155:579-586.
Study Question: Does the addition of clopidogrel to aspirin
provide net clinical benefit in patients with atrial fibrillation
(AF)?
Methods: This was a post-hoc analysis of 10,041 patients
with AF in the ACTIVE A and ACTIVE B trials in which
a vitamin K antagonist (VKA), aspirin (75-100 mg/day),
and aspirin plus clopidogrel (75 mg/day) were compared.
The endpoints consisted of ischemic stroke, intracerebral
hemorrhage, subdural hematoma, major extracranial hemor-
rhage, and myocardial infarction. These endpoints were
weighted using three different weighting systems based on
clinical impact. In one of the weighting systems, a weight
of 1.5 was given to intracerebral hemorrhage or subdural
hematoma, 1.0 to ischemic stroke, and 0 to extracranial
hemorrhage or myocardial infarction. Net clinical benefit
was calculated based on the incidence of each endpoint and
the weighted sum of those rates in the treatment groups
minus the weighted sum of endpoints in the placebo group. 
Results: With no weighting, adding clopidogrel to aspirin did
not have significant net clinical benefit. With weighting,
Summaries of Key Journal Articles
Kim A. Eagle, MD, Editor-in-Chief, Journal Scan, Ann Arbor, MI
Christopher P. Cannon, MD, Editor-in-Chief, CardioSource, Boston, MA
William F. Armstrong, MD, Ann Arbor, MI, David S. Bach, MD, Ann Arbor, MI, Ragavendra R.
Baliga, MBBS, Columbus, OH, Anna M. Booher, MD, Ann Arbor, MI, Timothy B. Cotts, MD, 
Ann Arbor, MI, Jennifer Cowger, MD, Ann Arbor, MI, Daniel T. Eitzman, MD, Ann Arbor, MI, 
James B. Froehlich, MD, Ann Arbor, MI, Caren S. Goldberg, MD, Ann Arbor, MI, Hitinder S. Gurm,
MBBS, Ann Arbor, MI, Jennifer C. Hirsch, MD, Ann Arbor, MI, Elizabeth Anne Jackson, MD, 
Ann Arbor, MI, Fred Morady, MD, Ann Arbor, MI, Debabrata Mukherjee, MD, El Paso, TX,
Himanshu J. Patel, MD, Ann Arbor, MI, John E. Rectenwald, MD, MS, Ann Arbor, MI, Melvyn
Rubenfire, MD, Ann Arbor, MI, Associate Editors, CardioSource
incidence of the primary outcome (hazard ratio [HR] 2.29),
death (HR 1.94), cardiovascular death (HR 2.11), arrhyth-
mic death (HR 3.26), stroke (2.32), and hospitalization for
heart failure (HR 1.81). 
Conclusions: Dronedarone increases the risk of death, stroke,
and heart failure in high-risk patients with PermAF. 
Perspective: The results of the ATHENA trial suggested that
dronedarone has benefits aside from restoration of sinus
rhythm, for example heart rate slowing, blood pressure
reduction, adrenergic blockade, or suppression of ventricular
arrhythmias. This was the rationale for the present study,
in which the patients were expected to remain in AF. The
mechanisms by which dronedarone worsened outcomes are
unclear, but could include a negative inotropic effect, ven-
tricular proarrhythmia, and/or an increase in serum digoxin
level.
Summary written by: Fred Morady, MD
Congenital Heart Disease
Long-Term Outcome of Patients With Isolated Thin
Discrete Subaortic Stenosis Treated by Balloon
Dilatation: A 25-Year Study
De Lezo JS, Romero M, Segura J, et al.
Circulation 2011;124:1461-1468.
Study Question: What are the long-term outcomes of patients
with discrete subaortic stenosis (DSS) treated with translu-
minal balloon dilatation? 
Methods: A retrospective review was performed at a single
center. Inclusion criteria required the presence of isolated
DSS with a thin (<3 mm) subaortic membrane with a signif-
icant gradient, left ventricular strain on electrocardiogram,
or symptoms. During the procedure, balloons were inflated
to a diameter size 1-2 mm larger than the aortic annulus.
The balloon was stabilized in the left ventricular outflow
tract with either administration of adenosine or rapid ven-
tricular pacing. 
Results: A total of 76 patients (mean age 19 ± 16 years)
underwent the procedure. The mean left ventricular outflow
tract gradient decreased from 70 ± 27 to 18 ± 12 mm Hg (p
< 0.001). One patient died after emergency surgery for wall
perforation, which occurred at the time of the procedure.
Over the follow-up period (mean 16 ± 6 years), 11 patients
developed restenosis, three patients progressed to muscular
obstructive disease, and one patient developed a new distant
obstructive membrane. Twelve patients underwent repeat
balloon dilatation at a mean of 5 ± 3 years after their first
procedure, and four patients underwent surgery at a mean
of 3 ± 2 years after their initial procedure. One patient was
found to have significant progression of aortic insufficiency
at follow-up. Larger aortic annulus diameter and thinner
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area pulmonary vein isolation (PVI) and optional supple-
mental ablation lines. SA consisted of PVI using a bipolar
RF ablation clamp, epicardial ganglia ablation, left atrial
appendage excision, and optional ablation lines. Efficacy
was assessed with serial 7-day Holter monitors. The primary
efficacy endpoint was freedom from AF/flutter/tachycardia
lasting >30 seconds off antiarrhythmic drug therapy at 12
months.   
Results: The primary efficacy endpoint was achieved signifi-
cantly more often by SA (65.6%) than by RFCA (36.5%).
The procedure-related complication rate also was signifi-
cantly higher with SA (23%) than with RFCA (3.2%).
The prevalence of significant adverse events during 12-
month follow-up was similar in both groups (11.5-12.7%).
Conclusions: In patients with AF and an enlarged left atrium
or prior unsuccessful catheter ablation, SA is more effica-
cious than RFCA, but associated with a several-fold higher
risk of procedure-related complications. 
Perspective: The study is notable because it is the first random-
ized comparison of SA versus RFCA for AF in patients with
an enlarged left atrium or prior failed ablation procedure.
A limitation of the study is that the ablation strategy in both
treatment groups was different at the two centers. However,
the efficacy rates were similar at both centers, indicating that
a non-uniform ablation strategy did not affect the results.
Summary written by: Fred Morady, MD
Dronedarone in High-Risk Permanent Atrial
Fibrillation
Connolly SJ, Camm AJ, Halperin JL, et al., on behalf of the
PALLAS Investigators.
N Engl J Med 2011;Nov 14:[Epub ahead of print]. 
Study Question: Does dronedarone improve outcomes in
high-risk patients with permanent atrial fibrillation
(PermAF)? 
Methods: In PALLAS, a multicenter double-blind study,
patients with PermAF for ≥6 months, age ≥65 years, and ≥1
risk factor (coronary artery disease, class II-III heart failure,
left ventricular ejection fraction ≤40%, peripheral artery dis-
ease, or the combination of age ≥75 years, hypertension, and
diabetes) were randomly assigned to receive dronedarone,
400 mg twice daily, or a matching placebo. The primary
outcome was a composite of stroke, myocardial infarction,
systemic embolism, or cardiovascular death. The intended
enrollment was 10,800 patients. 
Results: The study was terminated for safety reasons after
enrollment of 3,236 patients (mean age 75 years). The
median follow-up was 3.5 months. Compared to placebo,
dronedarone significantly reduced the mean heart rate by 7
bpm and increased the corrected QT by a mean of 6 ms.
Dronedarone was associated with significant increases in the
the very high SBP group (AHR, 2.08). For the secondary
composite outcome, the risk was higher among patients in
the very low–normal SBP group (AHR, 1.31), in the low-
normal (AHR, 1.16), in the high (AHR, 1.24), and in the
very high SBP group (AHR, 1.94). 
Conclusions: Among patients with recent non–cardioembolic
ischemic stroke, SBP levels during follow-up in the very
low–normal, high, or very high range were associated with
increased risk of recurrent stroke. 
Perspective: These data suggest a lack of benefit to lowering
SBP <130 mm Hg among patients with recent non–cardio-
embolic ischemic stroke. Randomized controlled trials to
fully evaluate this hypothesis prior to changes in guideline
recommendations are warranted.
Summary written by: Elizabeth A. Jackson, MD
Niacin in Patients With Low HDL Cholesterol Levels
Receiving Intensive Statin Therapy
The AIM-HIGH Investigators.
N Engl J Med 2011;Nov 15:[Epub ahead of print]. 
Study Question: Is extended-release niacin added to sim-
vastatin superior to simvastatin alone for reducing the risk
of cardiovascular events? 
Methods: A total of 3,414 patients with established cardiovas-
cular disease (stable coronary, carotid, or peripheral vascular
disease) were randomly assigned to receive extended-release
niacin, 1500-2000 mg/day, or matching placebo. All patients
received simvastatin, 40-80 mg/day and if needed ezetimibe
10 mg/day to maintain the low-density lipoprotein choles-
terol (LDL-C) between 40 and 80 mg/dl. Eligible patients
had a baseline low high-density lipoprotein cholesterol
(HDL-C) (<40 mg/dl for men and <50 mg/dl for women),
triglycerides 150-400 mg/dl, and LDL-C <180 mg/dl, if not
on a statin. Primary endpoint was the composite of the first
event of death from coronary heart disease, nonfatal myocar-
dial infarction, ischemic stroke, hospitalization for an acute
coronary syndrome, or symptom-driven coronary or cerebral
revascularization.  
Results: At baseline, mean age was 64 years, 85% were male,
71.4% had hypertension, and 33.9% diabetes. Niacin was
stopped in 25% of patients and placebo (containing 50 mg
of niacin) was stopped in 20.1% (p < 0.001). Significantly
more patients in the placebo group were taking simvastatin
80 mg/day (24.7% vs. 17.5%) and ezetamibe (21.5% vs.
9.5%). The trial was stopped after a mean follow-up of 3
years due to lack of efficacy. At 2 years, niacin therapy was
associated with an increase in median HDL-C from 35
mg/dl to 42 mg/dl, decrease in triglycerides from 164 mg/dl
to 122 mg/dl, and decrease in LDL-C from 74 mg/dl to 62
mg/dl. At 1 year, niacin was associated with an increase in
apolipoprotein A-1 from 122 mg/dl to 131 mg/dl, reduction
subaortic membrane were independently associated with
better long-term results. 
Conclusions: In a majority of patients, transluminal balloon
tearing of a discrete subaortic membrane is associated with
sustained relief without restenosis, need for surgery, progres-
sion to muscular obstructive disease, or an increase in the
degree of aortic regurgitation.
Perspective: Percutaneous treatment of DSS is not widely
used, with most centers favoring surgical intervention.
This study reports quite reasonable short- and long-term
results of balloon tearing of discrete subaortic membrane at
a single center. The study was performed at a single, highly
experienced center, and results may not be generalizable to
other centers. However, this study does suggest that a per-
cutaneous approach to DSS may be reasonable for some
patients.
Summary written by: Timothy B. Cotts, MD
General Cardiology
Level of Systolic Blood Pressure Within the Normal
Range and Risk of Recurrent Stroke
Ovbiagele B, Diener HC, Yusuf S, et al., on behalf of the PROFESS
Investigators.
JAMA 2011;306:2137-2144.
Study Question: What is the association of systolic blood pres-
sure (SBP) and risk for vascular events among patients with
a recent ischemic stroke? 
Methods: This was a post-hoc analysis using data from
PROFESS, a multicenter trial involving 20,330 patients
(ages ≥50 years) with recent non–cardioembolic ischemic
stroke, recruited from September 2003 through July 2006.
The trial used a 2 x 2 factorial design to compare a combi-
nation of aspirin and extended-release dipyridamole versus
clopidogrel and telmisartan or placebo. Patients were cate-
gorized based on their mean SBP level: very low–normal
(<120 mm Hg), low-normal (120-<130 mm Hg), high-
normal (130-<140 mm Hg), high (140-<150 mm Hg),
and very high (≥150 mm Hg). The primary outcome was
first recurrence of stroke of any type. The secondary out-
come was a composite outcome of stroke, myocardial
infarction, or death from vascular causes. 
Results: Among the 20,330 patients, the mean age was 66.1
years and 36% were female. The recurrent stroke rates were
8.0% for the very low–normal SBP level group, 7.2% for
low-normal, 6.8% for high-normal, 8.7% for high, and
14.1% for the very high SBP group. Compared with patients
in the high-normal SBP group, the risk of recurrence of
stroke of any type was higher for patients in the very low–
normal SBP group (adjusted hazard ratio [AHR], 1.29).
The risk was also elevated in the high (AHR, 1.23), and in
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in apo B from 81 mg/dl to 70 mg/dl, and decrease in Lp(a)
from 36 mg/dl to 27.1 mg/dl. The primary endpoint
occurred in 16.4% in the niacin group and 16.2% in the
placebo group. There was an increase in ischemic stroke as
the first event in those on niacin (1.6% vs. 0.9%). 
Conclusions: Among patients with atherosclerotic cardiovascu-
lar disease and LDL-C levels of <70 mg/dl, there was no
incremental benefit from the addition of niacin to statin ther-
apy during 36-month follow-up, despite significant
improvements in all lipid parameters. 
Perspective: As with so many other clinical trials in coronary
disease that fail to establish the benefit of an additional drug
or higher dosing as compared to conventional treatment,
AIM-HIGH may have suffered from an unexpected low
event rate, the effect of pre-trial statin therapy which reduces
plaque instability, inadequate follow-up, the imbalance of
statin dosing and addition of ezetamibe favoring the placebo,
and the low risk of the study cohort.
Summary written by: Melvyn Rubenfire, MD
Thrombin-Receptor Antagonist Vorapaxar in Acute
Coronary Syndromes
Tricoci P, Huang Z, Held C, et al., on behalf of the TRACER
Investigators.
N Engl J Med 2011;Nov 13:[Epub ahead of print].
Study Question: Does the addition of vorapaxar to the treat-
ment of acute non–ST-segment elevation myocardial
infarction (NSTEMI) reduce cardiovascular ischemic event
rates or improve outcomes without safety concerns? 
Methods: The TRACER trial investigators reported results
of a double-blind, placebo-controlled, multinational study
comparing the effect of vorapaxar (40 mg loading dose, fol-
lowed by 2.5 mg daily, orally) with placebo in patients who
were over age 55, or had a history of coronary artery or
peripheral artery disease, presenting with NSTE acute coro-
nary syndrome (ACS), defined by symptoms with either
cardiac enzyme elevation or dynamic ST-segment changes.
The primary endpoint was a composite of death from car-
diovascular causes, MI, stroke, rehospitalization for
recurrent ischemia, or urgent revascularization. 
Results: Follow-up of 12,944 randomized patients was termi-
nated early after safety review. Median follow-up was 502
days. The primary endpoint 2-year rate was 18.5% versus
19.9% in the vorapaxar and placebo groups, respectively
(hazard ratio [HR], 0.92). Secondary endpoint of composite
of death from cardiovascular cause, MI, or stroke had a rate
of 14.7% versus 16.4% in the vorapaxar and placebo groups,
respectively (HR, 0.89). Moderate and severe bleeding rates
in the vorapaxar and placebo groups were 7.2% and 5.2%,
respectively (HR, 1.35), and the intracranial hemorrhage
rates were 1.1% and 0.2%, respectively (HR, 3.39). 
Conclusions: In patients with ACS, the addition of vorapaxar to
standard therapy did not significantly reduce the primary com-
posite endpoint, but significantly increased the risk of major
bleeding, including intracranial hemorrhage.
Perspective: This very large and rigorously conducted multina-
tional study of a thrombin-receptor antagonist in NSTE ACS
was stopped early due to safety concerns, specifically a roughly
35% increase in moderate and severe bleeding, as well as a
more than threefold increase in intracranial hemorrhage rate.
The data suggest that we may be reaching the limit of multi-
modal antiplatelet therapy to provide further efficacy
improvement without conferring further bleeding risk.
Summary written by:  James B. Froehlich, MD, MPH
Apixaban Versus Enoxaparin for
Thromboprophylaxis in Medically Ill Patients
Goldhaber SZ, Leizorovicz A, Kakkar AK, et al., on behalf of the
ADOPT Trial Investigators.
N Engl J Med 2011;Nov 13:[Epub ahead of print].
Study Question: Is extended-duration thromboembolism pro-
phylaxis with apixaban more effective than short-term
prophylaxis with enoxaparin in hospitalized medically ill
patients? 
Methods: The ADOPT trial investigators reported the results
of a double-blind, double-dummy, placebo-controlled trial
of orally administered apixaban at a dose of 2.5 mg twice
daily for 30 days, versus subcutaneously administered enoxa-
parin at a dose of 40 mg once daily for 6 to 14 days, in
acutely ill hospitalized medical patients. Subjects had to be
40 years of age or older, and hospitalized for congestive heart
failure, acute respiratory failure, infection without shock,
inflammatory bowel disease, or acute rheumatic disorder,
with an expected hospital stay of at least 3 days. Systematic,
bilateral, compression ultrasonography was performed on day
30. The primary efficacy outcome was 30-day composite of
death related to venous thromboembolism, pulmonary
embolism, symptomatic deep-vein thrombosis (DVT), or
asymptomatic DVT. 
Results: Out of 6,528 randomized subjects, 4,495 could be
evaluated for the primary outcome. The primary outcome at
30 days was seen in 2.71% of subjects in the apixaban group
versus 3.06% in the enoxaparin group (relative risk [RR],
0.87; 95% confidence interval [CI], 0.62-1.23; p = 0.44).
Major bleeding was seen in 0.47% versus 0.19%, in the apix-
aban versus enoxaparin groups, respectively (RR, 2.58; 95%
CI, 1.02-7.24; p = 0.04). 
Conclusions: In medically ill patients, an extended course of
thromboprophylaxis with apixaban was not superior to a
shorter course of enoxaparin. Apixaban was associated with
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this approach may work. However, this is an interim analysis
from an ongoing study and additional patients and follow-up
will be needed to confirm these exciting preliminary results.
Summary written by: Daniel T. Eitzman, MD
Interventional
Abciximab and Heparin Versus Bivalirudin for
Non–ST-Elevation Myocardial Infarction
Kastrati A, Neumann FJ, Schulz S, et al., on behalf of the
ISAR-REACT 4 Trial Investigators.
N Engl J Med 2011;Nov 13:[Epub ahead of print].
Study Question: What is the effect of abciximab with unfrac-
tionated heparin, as compared with bivalirudin, on clinical
outcomes in patients with acute non–ST-segment elevation
myocardial infarction (NSTEMI) undergoing percutaneous
coronary intervention (PCI)? 
Methods: The ISAR-REACT 4 trial investigators randomly
assigned, in a double-blind manner, 1,721 patients with
acute NSTEMI to receive abciximab plus unfractionated
heparin (861 patients) or bivalirudin (860 patients). The
study tested the hypothesis that abciximab and heparin
would be superior to bivalirudin with respect to the primary
composite endpoint of death, large recurrent MI, urgent tar-
get vessel revascularization (TVR), or major bleeding within
30 days.
Results: The primary endpoint occurred in 10.9% of the
patients in the abciximab (94 patients) and in 11.0% in the
bivalirudin group (95 patients) (relative risk [RR] with abcix-
imab, 0.99; p = 0.94). Death, any recurrent MI, or urgent
TVR occurred in 12.8% of the patients in the abciximab
(110 patients) and in 13.4% in the bivalirudin group (RR,
0.96; p = 0.76). Major bleeding occurred in 4.6% of the
patients in the abciximab compared with 2.6% in the
bivalirudin group (RR, 1.84; 95% CI, 1.10-3.07; p = 0.02). 
Conclusions: Abciximab and unfractionated heparin, as com-
pared with bivalirudin, failed to reduce the rate of the
primary endpoint and increased the risk of bleeding among
patients with NSTEMI who were undergoing PCI. 
Perspective: This randomized study reports that abciximab
plus unfractionated heparin, compared with bivalirudin, was
not associated with a reduction in the risk of death, large
recurrent MI, urgent TVR, or major bleeding at 30 days.
Furthermore, incidence of major bleeding was significantly
increased with abciximab plus unfractionated heparin. The
results of the current trial in conjunction with other available
evidence support the use of bivalirudin as the preferred
antithrombotic drug during PCI in patients with NSTEMI.
Summary written by: Debabrata Mukherjee, MD
Perspective: Apixaban can now join rivaroxaban and enoxaparin
as agents demonstrated to effectively prevent DVT in high-
risk situations such as in medically ill, hospitalized, at-risk
patients, but also demonstrated an increased risk of major
bleeding when prophylaxis treatment is extended. Unless a
targeted population at higher risk can be identified for pro-
phylaxis treatment, extended-duration thromboembolism
prophylaxis for hospitalized medically ill patients cannot be
recommended.
Summary written by: James B. Froehlich, MD, MPH
Heart Failure/Transplant
Cardiac Stem Cells in Patients With Ischaemic
Cardiomyopathy (SCIPIO): Initial Results of a
Randomised Phase 1 Trial
Bolli R, Chugh AR, D’Amario D, et al.
Lancet 2011;Nov 14:[Epub ahead of print].
Study Question: What is the effect of cardiac stem cell (CSC)
infusion on post-myocardial infarction (MI) left ventricular
(LV) function? 
Methods: Patients with post-MI LV dysfunction (ejection
fraction [EF] ≤40%) before CABG were randomly assigned
to treatment or control group (2:3 ratio). One million auto-
logous c-kit-positive, lineage-negative CSCs were
administered by intracoronary infusion 113 days after sur-
gery, whereas the control group received no treatment. The
primary endpoint was short-term safety of CSCs and the
secondary endpoint was efficacy. 
Results: No CSC-related adverse effects were reported. In
14 CSC-treated patients, LVEF increased from 30.3 ± 1.9%
before CSC infusion to 38.5 ± 2.8% at 4 months following
infusion (p = 0.001), whereas in seven control patients,
LVEF did not change (30.1 ± 2.4% vs. 30.2 ± 2.5%). The
beneficial effects of CSCs were even more pronounced at 1
year in eight patients (LVEF increased by 12.3 ± 2.1% vs.
baseline, p = 0.0007). In seven treated patients, MRI con-
firmed a significant reduction in infarct size at 4 months
and 1 year. 
Conclusions: Intracoronary infusion of autologous CSCs is
effective in improving LV systolic function and reducing
infarct size in patients with heart failure after myocardial
infarction, and warrant further, larger, phase 2 studies.
Perspective: Repair of infarcted myocardium remains one of
the holy grails of cardiology. Cell-based therapies hold great
promise, but several previous clinical studies have reported
modest or negative results. Even in trials with positive
results, the mechanism(s) by which transplanted cells confer
benefit remains obscure. The current trial casts a ray of hope
on this field and suggests that if the correct cell type is used,
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Benefit of Transferring ST-Segment–Elevation
Myocardial Infarction Patients for Percutaneous
Coronary Intervention Compared With
Administration of Onsite Fibrinolytic Declines as
Delays Increase
Pinto DS, Frederick PD, Chakrabarti AK, et al., on behalf of the
National Registry of Myocardial Infarction Investigators.
Circulation 2011;Nov 7:[Epub ahead of print].
Study Question: What is the clinical impact of delays in trans-
fer for primary percutaneous coronary intervention (PCI) in
ST-segment elevation myocardial infarction (STEMI) com-
pared with onsite fibrinolytic therapy in routine clinical
practice?
Methods: The authors assessed the outcome of patients who
presented with STEMI within 12 hours of symptom onset
and were enrolled in the National Registry of Myocardial
Infarction (NRMI). Propensity matching of patients trans-
ferred for PCI and treated with onsite fibrinolysis was
performed. The effect of PCI-related delay on in-hospital
mortality was assessed—calculated by subtracting the door-
to-balloon time from the door-to-needle time. 
Results: The study cohort was comprised of 9,506 patients
who were transferred for PCI, and matched with 9,506
patients treated with onsite fibrinolysis. In the matched
cohort, PCI was performed with delays >90 minutes in
68%. After adjusting for baseline differences, there was no
mortality advantage of transfer for PCI when the door-to-
balloon time exceeded the door-to-needle time by 120
minutes. The mortality advantage with PCI was highest
when the treatment delay was <60 minutes (2.7% vs. 7.4%),
of smaller magnitude with delay of 60-90 minutes (3.6% vs.
5.5%), and absent when the delay exceeded 90 minutes
(5.7 % vs. 6.1%). PCI was associated with an advantage for
all measured clinical endpoints among patients in the lowest
tertile (median, 63 minutes). In the second tertile of delay
(median, 119 minutes), there was no survival benefit, but
there was a reduction in the composite endpoint of
death/MI and death/MI/stroke. 
Conclusions: Transfer for PCI is superior to onsite fibrinolytics,
although the survival benefit of PCI diminishes with increas-
ing treatment delay.
Perspective: This study confirms the superiority of transfer
for PCI over onsite fibrinolysis in patients with STEMI.
While PCI was superior to, or no different than onsite fib-
rinolysis, the dramatic survival advantage associated with
treatment delays of <60 minutes, invokes the need to
develop national systems for rapid triage and transfer of
patients presenting to non-PCI hospitals.
Summary written by: Hitinder S. Gurm, MBBS
Prevention/Vascular
Rivaroxaban in Patients With a Recent Acute
Coronary Syndrome
Mega JL, Braunwald E, Wiviott SD, et al., on behalf of the
ATLAS ACS 2–TIMI 51 Investigators.
N Engl J Med 2011;Nov 13:[Epub ahead of print].
Study Question: What is the effect of low-dose rivaroxaban on
cardiovascular outcomes in patients with a recent acute coro-
nary syndrome (ACS)? 
Methods: ATLAS ACS 2–TIMI 51 was a double-blind,
placebo-controlled trial. The investigators randomly assigned
15,526 patients with a recent ACS to receive twice-daily doses
of either 2.5 mg or 5 mg of rivaroxaban or placebo for a mean
of 13 months and up to 31 months. The primary efficacy end-
point was a composite of death from cardiovascular causes,
myocardial infarction, or stroke. 
Results: Rivaroxaban significantly reduced the primary efficacy
endpoint, compared with placebo, with respective rates of
8.9% and 10.7% (hazard ratio in the rivaroxaban group, 0.84;
p = 0.008), with significant improvement for both the twice-
daily 2.5 mg dose (9.1% vs. 10.7%, p = 0.02) and the
twice-daily 5 mg dose (8.8% vs. 10.7%, p = 0.03). The twice-
daily 2.5 mg dose of rivaroxaban reduced the rates of death
from cardiovascular causes (2.7% vs. 4.1%, p = 0.002) and
from any cause (2.9% vs. 4.5%, p = 0.002), a survival benefit
that was not seen with the twice-daily 5 mg dose. As com-
pared with placebo, rivaroxaban increased the rates of major
bleeding not related to coronary artery bypass grafting (2.1%
vs. 0.6%, p < 0.001) and intracranial hemorrhage (0.6% vs.
0.2%, p = 0.009), without a significant increase in fatal bleed-
ing (0.3% vs. 0.2%, p = 0.66) or other adverse events. The
twice-daily 2.5 mg dose resulted in fewer fatal bleeding events
than the 5 mg dose (0.1% vs. 0.4%, p = 0.04). 
Conclusions: In patients with a recent ACS, rivaroxaban
reduced the risk of the composite endpoint of death from car-
diovascular causes, myocardial infarction, or stroke. 
Perspective: In this study, the two doses of rivaroxaban
increased the rates of major bleeding and intracranial hemor-
rhage, compared with placebo, without a significant increase
in fatal bleeding. Furthermore, the lower dose of rivaroxaban
resulted in less bleeding than the higher dose. The addition of
very-low-dose anticoagulation with rivaroxaban may represent
a new treatment strategy in ACS patients, but additional stud-
ies are needed to balance ischemic versus bleeding risks when
selecting the type, number, and duration of antithrombotic
therapies for individual patients.
Summary written by:  Debabrata Mukherjee, MD
6 Eagle, Cannon
Scanning the Literature
JACC Vol. 59, No. 1, 2012
December 27, 2011/January 3, 2012:1-8
Dosing Clopidogrel Based on CYP2C19 Genotype and
the Effect on Platelet Reactivity in Patients With
Stable Cardiovascular Disease
Mega JL, Hochholzer W, Frelinger AL III, et al.
JAMA 2011;306:2221-2228.
Study Question: What is the effect of higher doses (up to 300
mg daily) of clopidogrel on response in the setting of loss of
function CYP2C19 genotype? 
Methods: ELEVATE-TIMI 56 was a multicenter, random-
ized, double-blind trial that enrolled and genotyped 333
patients with cardiovascular disease across 32 sites.
Maintenance doses of clopidogrel for four treatment peri-
ods, each lasting approximately 14 days, were based on
genotype. In total, 247 noncarriers of CYP2C19*2 loss of
function allele were to receive 75 and 150 mg of clopidogrel
daily (two periods each), whereas 86 carriers (80 heterozy-
gotes, 6 homozygotes) were to receive 75, 150, 225, and 300
mg daily. The main outcome measures were platelet func-
tion test results (vasodilator-stimulated phosphoprotein
[VASP] phosphorylation and VerifyNow P2Y12 assays)
and adverse events. 
Results: With 75 mg daily, CYP2C19*2 heterozygotes had
significantly higher on-treatment platelet reactivity than did
noncarriers (VASP platelet reactivity index [PRI]: mean,
70.0% vs. 57.5%, and VerifyNow P2Y12 reaction unit
[PRU]: mean 225.6 vs. 163.6; p < 0.001 for both compar-
isons). Among CYP2C19*2 heterozygotes, doses up to 300
mg daily significantly reduced platelet reactivity with VASP
PRI decreasing to 48.9% and PRU to 127.5 (p < 0.001 for
for both). Whereas 52% of CYP2C19*2 heterozygotes were
nonresponders (≥230 PRU) with 75 mg of clopidogrel, only
10% were nonresponders with 225 or 300 mg (p < 0.001 for
both). Clopidogrel, 225 mg daily, reduced platelet reactivity
in CYP2C19*2 heterozygotes to levels achieved with stan-
dard clopidogrel, 75 mg, in noncarriers (mean ratios of
platelet reactivity, VASP PRI 0.92, and PRU, 0.94).
Conclusions: Among patients with stable cardiovascular dis-
ease, tripling the maintenance dose of clopidogrel to 225 mg
daily in CYP2C19*2 heterozygotes achieved levels of platelet
reactivity similar to that seen with 75 mg in noncarriers, but
doses up to 300 mg in CYP2C19*2 homozygotes did not result
in a comparable degree of platelet inhibition. 
Perspective: This study suggests that daily maintenance of ≥225
mg of clopidogrel in CYP2C19*2 heterozygotes can achieve
platelet reactivity comparable to that achieved with 75 mg in
noncarriers with cardiovascular disease. Further studies are
indicated to ascertain whether these higher doses of clopido-
grel translate into better clinical outcomes in CYP2C19*2
heterozygotes.
Summary written by: Debabrata Mukherjee, MD
Full Coverage for Preventive Medications After
Myocardial Infarction
Choudhry NK, Avorn J, Glynn RJ, et al., on behalf of the Post-
Myocardial Infarction Free Rx Event and Economic Evaluation
(MI FREEE) Trial.
JAMA 2011;Nov 14:[Epub ahead of print].
Study Question: What is the effect of elimination of out-of-
pocket costs for evidence-based therapies after myocardial
infarction on adherence and clinical outcomes? 
Methods: The investigators enrolled patients discharged after
myocardial infarction and randomly assigned their insurance-
plan sponsors to full prescription coverage (1,494 plan
sponsors with 2,845 patients) or usual prescription coverage
(1,486 plan sponsors with 3,010 patients) for all statins, beta-
blockers, angiotensin-converting enzyme inhibitors, or
angiotensin-receptor blockers. The primary outcome was the
first major vascular event or revascularization. Secondary out-
comes were rates of medication adherence, total major
vascular events or revascularization, the first major vascular
event, and health expenditures.  
Results: Rates of adherence ranged from 35.9% to 49.0%
in the usual-coverage group and were 4-6 percentage points
higher in the full-coverage group (p < 0.001 for all compar-
isons). There was no significant between-group difference
in the primary outcome (17.6 per 100 person-years in the
full-coverage group vs. 18.8 in the usual coverage group;
p = 0.21). The rates of total major vascular events or revas-
cularization were significantly reduced in the full-coverage
group (21.5 vs. 23.3; p = 0.03), as was the rate of the first
major vascular event (11.0 vs. 12.8; p = 0.03). The elimina-
tion of copayments did not increase total spending
($66,008 for the full-coverage group and $71,778 for the
usual-coverage group; relative spending, 0.89; p = 0.68).
Patient costs were reduced for drugs and other services
(relative spending, 0.74; p < 0.001).  
Conclusions: Enhanced prescription coverage improved medica-
tion adherence and rates of first major vascular events. 
Perspective: This study suggests that the elimination of copay-
ments for these drugs did not significantly improve first
major cardiovascular events or revascularization. The inter-
vention, however, increased medication adherence and
reduced the rates of first major and total major vascular
events or revascularization. The enhanced coverage reduced
patients’ out-of-pocket spending and did not significantly
change total spending by insurers or overall costs. This strat-
egy shows promise, may contribute significantly to ongoing
efforts to improve the quality of care for patients after
myocardial infarction, and may improve outcomes.  
Summary written by: Debabrata Mukherjee, MD
JACC Vol. 59, No. 1, 2012
December 27, 2011/January 3, 2012:1-8
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Effects of the CETP Inhibitor Evacetrapib
Administered as Monotherapy or in Combination
With Statins on HDL and LDL Cholesterol: A
Randomized Controlled Trial
Nicholls SJ, Brewer HB, Kastelein JJ, et al.
JAMA 2011;306:2099-2109.
Study Question: What are the biochemical effects, safety, and
tolerability of evacetrapib, as monotherapy and in combina-
tion with statins, in patients with dyslipidemia? 
Methods: This randomized controlled trial was conducted
among 398 patients with elevated low-density lipoprotein cho-
lesterol (LDL-C) or low high-density lipoprotein cholesterol
(HDL-C) (<45 mg/dl for men and <50 mg/dl for women) lev-
els from April 2010 to January 2011 at centers in the United
States and Europe. Following dietary lead-in, patients were
randomly assigned to receive placebo (n = 38); evacetrapib
monotherapy, 30 mg/d (n = 40), 100 mg/d (n = 39), or 500
mg/d (n = 42); or statin therapy (n = 239) (simvastatin, 40
mg/d; atorvastatin, 20 mg/d; or rosuvastatin, 10 mg/d) with
or without evacetrapib, 100 mg/d, for 12 weeks. 
Results: Baseline variables in the monotherapy evacetrapib
and in combination with statins were similar. The mean base-
line HDL-C level was 55.1 mg/dl, and LDL-C level was
144.3 mg/dl. As monotherapy, evacetrapib produced dose-
dependent increases in HDL-C of 30.0-66.0 mg/dl compared
with a decrease with placebo of −0.7 mg/dl and decreases in
LDL-C of −20.5 to −51.4 mg/dl compared with an increase
with placebo of 7.2 mg/dl. In combination with statin ther-
apy, evacetrapib, 100 mg/d, produced increases in HDL-C
of 42.1-50.5 mg/dl and decreases in LDL-C of −67.1 to
−75.8 mg/dl. Compared with evacetrapib monotherapy, the
combination of statins and evacetrapib resulted in greater
reductions in LDL-C (p < 0.001).
Conclusions: Compared with placebo or statin monotherapy,
evacetrapib as monotherapy or in combination with statins
increased HDL-C levels and decreased LDL-C levels. The
effects on cardiovascular outcomes require further investiga-
tion. 
Perspective: Statin therapy can reduce the LDL-C to targets
in most patients with atherosclerosis or increased risk. But the
reduction in cardiovascular events with statins compared to
placebo is in the range of 25%, and HDL-C levels remain a
risk predictor on statins.  HDL-C is the remaining major risk
factor for which there is not yet clinical evidence of a treat-
ment benefit. Evacetrapib offers the best opportunity to
determine the value of increasing the HDL-C and
apolipoprotein A-1.
Summary written by: Melvyn Rubenfire, MD 
Effect of Two Intensive Statin Regimens on
Progression of Coronary Disease
Nicholls SJ, Ballantyne CM, Barter PJ, et al.
N Engl J Med 2011;Nov 15:[Epub ahead of print].
Study Question: What is the relative efficacy of maximal
approved doses of atorvastatin and rosuvastatin on coronary
disease regression? 
Methods: In the SATURN trial, serial intravascular ultra-
sonography (IVUS) was performed in 1,039 patients with
coronary disease, at baseline and after 104 weeks of treat-
ment with either atorvastatin, 80 mg daily, or rosuvastatin,
40 mg daily. Patients ages 18-75 years were eligible if they
had at least one vessel with a 20% stenosis and a target vessel
for IVUS with <50% stenosis. Entry low-density lipoprotein
cholesterol (LDL-C) levels were required to be >100 mg/dl
off statins and >80 mg/dl on statins. Primary efficacy end-
point was the change in percent atheroma volume, and
secondary endpoint was normalized total atheroma volume. 
Results: Groups were similar for: mean age 57.5 years,
>70% male, 95% white, >70% hypertension, and about
60% had prior use of statins. Mean LDL-C was 120
mg/dl, high-density lipoprotein cholesterol (HDL-C) 45
mg/dl, apolipoprotein (apo) B 105 mg/dl, apo A-1 127
mg/dl, and apoB/apoA-2 0.9 mg/dl. After 104 weeks of
therapy, the rosuvastatin group had lower levels of LDL-C
than the atorvastatin group (62.6 vs. 70.2 mg/dl), and
higher levels of HDL-C (50.4 vs. 48.6 mg/dl). The pri-
mary endpoint of percent atheroma volume decreased by
0.99% with atorvastatin and by 1.22% with rosuvastatin (p
= 0.17). The normalized total atheroma volume was more
favorable with rosuvastatin than with atorvastatin:
-6.39 mm3 compared with -4.42 mm3 (p = 0.01). 
Conclusions: Maximal doses of rosuvastatin and atorvastatin
resulted in significant regression of coronary atherosclerosis.
Despite the lower level of LDL-C and the higher level of
HDL-C achieved with rosuvastatin, a similar degree of
regression of percent atheroma volume was observed.
Perspective: This elegant study adds to the evidence that
intense statin dosing can be associated with regression of
atherosclerotic plaque, and that the high-dose very potent
statins are safe. The study size and duration were not ade-
quate to determine whether the better lipid profile achieved
with rosvastatin compared to atorvastatin would provide any
clinical benefit.
Summary written by: Melvyn Rubenfire, MD
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